Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00091650
Status:
COMPLETED
Last Update Posted:
2006-07-24
First Post:
2004-09-14
Brief Title:
Olanzapine in Patients With Borderline Personality Disorder
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder A Randomized Flexible Dose Double-Blind Comparison With Placebo
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goals of this study are to determine the safety of olanzapine and any side effects that might be associated with it how olanzapine compares to placebo whether olanzapine can help patients with symptoms of Borderline Personality Disorder BPD and how much olanzapine should be given to patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F1D-MC-HGKL | None | None | None |